Lupus News and Research RSS Feed - Lupus News and Research

Systemic lupus erythematosus (SLE), also called lupus, is an autoimmune disorder characterized by the immune system attacking the body's own tissues and organs, leading to inflammation and damage. The severity of the disease varies, from mild cases only involving the skin to severe cases affecting multiple organs, including the brain. Lupus sufferers experience flares, or intervals of active disease, and remissions in disease. The disease most predominantly occurs in women of childbearing age, but also affects children, adolescents, and men. While the cause of lupus is still unknown, various genetic, environmental, and infectious causes have been associated with its development. Current treatments for lupus vary depending on the extent of the disease, and may change over time. Some medications used to ease symptoms include nonsteroidal anti-inflammatory drugs, antimalarial drugs, corticosteroids, and immunosuppressive medications, though many of these drugs carry their own risks.
Lactobacillus-containing probiotics could improve lupus symptoms

Lactobacillus-containing probiotics could improve lupus symptoms

Lactobacillus species, commonly seen in yogurt cultures, correlate, in the guts of mouse models, with mitigation of lupus symptoms, while Lachnospiraceae, a type of Clostridia, correlate with worsening, according to research published ahead of print in Applied and Environmental Microbiology. [More]
Scientists identify two microRNA molecules that control chronic inflammation

Scientists identify two microRNA molecules that control chronic inflammation

University of Utah scientists have identified two microRNA molecules that control chronic inflammation, a discovery that one day may help researchers prevent certain fatal or debilitating conditions before they start. [More]
Researchers identify two microRNA molecules that control chronic inflammation

Researchers identify two microRNA molecules that control chronic inflammation

University of Utah scientists have identified two microRNA molecules that control chronic inflammation, a discovery that one day may help researchers prevent certain fatal or debilitating conditions before they start. [More]
OMRF scientist selected to receive EMD Serono's Grant for Multiple Sclerosis Innovation

OMRF scientist selected to receive EMD Serono's Grant for Multiple Sclerosis Innovation

An Oklahoma Medical Research Foundation scientist has been selected to receive one of only five Grants for Multiple Sclerosis Innovation awarded this year by the pharmaceutical company EMD Serono. [More]

Eli Lilly to discontinue development of tabalumab due to insufficient efficacy in Phase 3 Lupus trials

Eli Lilly and Company announced today it will discontinue development of tabalumab­ -- being studied for the treatment of systemic lupus erythematosus (SLE, commonly known as lupus) -- due to insufficient efficacy in two pivotal Phase 3 trials. The decision was not based on safety concerns. ­­­­ [More]
Mission Pharmacal adds Ovace Plus Lotion to its range of product offerings

Mission Pharmacal adds Ovace Plus Lotion to its range of product offerings

Itch. Scratch. Repeat. Irritating skin conditions, such as seborrheic dermatitis (SD), can create a distracting, uncomfortable vicious circle for those affected. [More]
New findings could pave way for treating autoimmune diseases

New findings could pave way for treating autoimmune diseases

Scientists from A*STAR's Bioprocessing Technology Institute (BTI) have established a clearer relationship between two cells which serve our body's natural defence mechanisms against diseases and infections. [More]
NIH awards grants to 11 research groups to establish AMP RA/Lupus Network

NIH awards grants to 11 research groups to establish AMP RA/Lupus Network

The National Institutes of Health has awarded grants to 11 research groups across the United States to establish the Accelerating Medicines Partnership in Rheumatoid Arthritis and Lupus (AMP RA/Lupus) Network. [More]
New findings raise hope for novel class of drugs to treat lupus

New findings raise hope for novel class of drugs to treat lupus

New findings by a biomedical engineer and his team at the University of Houston raise hope for a new class of drugs to treat lupus that may not include the long list of adverse risks and side effects often associated with current treatments for this disease. [More]
AbbVie’s Phase 3 pivotal study shows HUMIRA is effective in reducing symptoms in HS

AbbVie’s Phase 3 pivotal study shows HUMIRA is effective in reducing symptoms in HS

AbbVie today announced results from a Phase 3 pivotal study demonstrating that HUMIRA® (adalimumab) is effective in reducing common clinical signs and symptoms in moderate-to-severe hidradenitis suppurativa (HS), specifically the number of abscesses and inflammatory nodules. [More]
Scientists identify how immune cells use two critical receptors to clear dead cells from the body

Scientists identify how immune cells use two critical receptors to clear dead cells from the body

In most of the tissues of the body, specialized immune cells are entrusted with the task of engulfing the billions of dead cells that are generated every day. [More]
LSDF announces $750,000 in Proof of Concept grants to promote health-related technologies

LSDF announces $750,000 in Proof of Concept grants to promote health-related technologies

The Life Sciences Discovery Fund (LSDF) today announced nearly $750,000 in Proof of Concept grants to Washington state for-profit and non-profit organizations to promote translation of health-related technologies from the laboratory to the commercial marketplace. [More]
Scientists make important breakthrough in fight against debilitating autoimmune diseases

Scientists make important breakthrough in fight against debilitating autoimmune diseases

Scientists have made an important breakthrough in the fight against debilitating autoimmune diseases such as multiple sclerosis by revealing how to stop cells attacking healthy body tissue. [More]
Researchers find method to expand blood stem cells used to treat cancer patients

Researchers find method to expand blood stem cells used to treat cancer patients

A team of scientists from the University of Colorado School of Medicine has reported the breakthrough discovery of a process to expand production of stem cells used to treat cancer patients. [More]
Rheumatologic diseases can initially present as neurological disorders, delay diagnosis for many months

Rheumatologic diseases can initially present as neurological disorders, delay diagnosis for many months

Lupus and other rheumatologic diseases can initially present as neurological disorders such as headaches and seizures, and thus delay diagnosis for many months, according to Loyola University Medical Center neurologists. [More]
Research roundup: Benefits of smaller practices; Rx price growth; fixing Medicare claims reviews

Research roundup: Benefits of smaller practices; Rx price growth; fixing Medicare claims reviews

The Centers for Medicare & Medicaid Services within the Department of Health and Human Services has taken steps to prevent its contractors from conducting certain duplicative postpayment claims reviews-;reviews of the same claims that are not permitted by the agency-;but CMS neither has reliable data nor provides sufficient oversight and guidance to measure and fully prevent duplication. [More]

Mortality predictors REVEALed for PAH in systemic sclerosis

Elderly men and patients with low baseline systolic blood pressure are among those at a particularly high risk of death from pulmonary arterial hypertension associated with systemic sclerosis, a US study has found. [More]
Experts examine how molecule in parasitic worms can effectively treat autoimmune diseases

Experts examine how molecule in parasitic worms can effectively treat autoimmune diseases

Experts believe a molecule in parasitic worms could help explain why worm infections can effectively treat a range of autoimmune diseases, including multiple sclerosis, psoriasis, rheumatoid arthritis and lupus. [More]
Black and Hispanic SLE patients are more likely to be readmitted than white patients

Black and Hispanic SLE patients are more likely to be readmitted than white patients

A new study reveals that one in six patients with systemic lupus erythematosus (SLE) is readmitted to the hospital within 30 days of being discharged. [More]
Idera collaborates with TMA to advance new potential treatment approach for myositis

Idera collaborates with TMA to advance new potential treatment approach for myositis

Idera Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing nucleic acid therapeutics for patients with cancer and rare diseases, and The Myositis Association (TMA), the only nonprofit organization dedicated to solely serving all patients with inflammatory myopathies, today announced a collaboration to advance a new potential treatment approach for polymyositis and dermatomyositis known as Toll-like receptor (TLR) antagonism. [More]